DRW Securities’s Prevail Therapeutics PRVL Stock Holding History
Bought
Maintained
Sold
Other funds holding PRVL
DRW Securities's PRVL Position: Q3 2019 in Review
DRW Securities sold out of Prevail Therapeutics (PRVL) in Q3 2019, closing a stake of 49,426 shares — an estimated $652K sold.
DRW Securities first reported a position in PRVL in Q2 2019 and held it in 1 quarter. The position peaked at $652K in Q2 2019. 42 funds tracked by Wall St. Rank hold PRVL as of Q3 2019.
- DRW Securities reported no remaining Prevail Therapeutics position as of Q3 2019 after selling out during the quarter.
- DRW Securities sold 49,426 Prevail Therapeutics shares in Q3 2019, an estimated $652K.
- DRW Securities first reported a position in Prevail Therapeutics in Q2 2019 and held it in 1 quarter.
- DRW Securities's Prevail Therapeutics position peaked at $652K in Q2 2019.
- 42 funds tracked by Wall St. Rank held Prevail Therapeutics as of Q3 2019.
Based on DRW Securities's 13F filing for Q3 2019, filed 14 Nov 2019.